Strategic partnerships Actylis has active and growing partnerships across pharma and chemical supply chains, including recent agreements with Novo Nordisk Pharmatech and Aarti Industries, signaling openness to collaboration with global suppliers and distributors to expand market reach in Canada, Europe, and North America.

Expanded product capabilities The company operates a hybrid model of GMP and non-GMP facilities with a strong sourcing hub network, offering standard and custom ingredients, which creates cross-sell opportunities for customers requiring both manufactured and sourced raw materials and turnkey supply solutions.

Recent M&A activity Past acquisitions and asset divestitures, including the Pharm Rxchem acquisition and the sale of a CDMO asset to Agno Pharma, indicate ongoing consolidation and strategic realignment that could open opportunities to position Actylis as a partner for customers seeking scale, risk management, and enhanced supply security.

Key leadership and growth New CEO appointment in 2024 and aggressive expansion evidenced by multiple partnerships and facility enhancements (e.g., Water for Injection launch and ISO class 7 capacity) suggest a growth trajectory with a focus on expanding high-value life sciences ingredients and specialty chemicals.

Geographic and sector reach Global footprint with distribution across multiple regions (Canada, Europe, UK, Nordics, Benelux, etc.) and emphasis on life sciences, VMS, and pharmaceutical ingredients position Actylis to target multinational manufacturers seeking reliable, compliant supply chains and integrated sourcing plus manufacturing.